Spatial genomic tools to interrogate T cell clonotypes, tumor clones and the microenvironment
用于询问 T 细胞克隆型、肿瘤克隆和微环境的空间基因组工具
基本信息
- 批准号:10565141
- 负责人:
- 金额:$ 69.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-02-01 至 2028-01-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdoptive TransferAffectAntigen TargetingAntigensAttentionAutomobile DrivingBiologicalCellsClinicalClinical PathologyClinical ProtocolsClone CellsCloningComplexCuesDNADNA sequencingDataDetectionDevelopmentEpitopesGenerationsGenetic HeterogeneityGenetic TranscriptionGenomicsGoalsGrowthHistologicHumanImageImmuneImmune responseImmune systemImmunityImmunotherapyIn SituInfiltrationKnowledgeLinkMalignant - descriptorMalignant NeoplasmsMapsMediatingMemoryMethodsMicroscopyModelingMolecularMusMutationNatureOutcomePatternPeptide/MHC ComplexPhenotypePopulationPositioning AttributeRNARenal Cell CarcinomaResolutionRoleSamplingScienceSlideSpace PerceptionSpecificitySpecimenStromal CellsSystemT cell infiltrationT cell receptor repertoire sequencingT cell responseT-Cell Antigen Receptor SpecificityT-Cell Immunologic SpecificityT-Cell ReceptorT-LymphocyteTechnologyTestingTissuesTranscriptTumor AntigensTumor ImmunityTumor TissueVaccinesViralViral AntigensWorkanalytical toolcancer infiltrating T cellscomputer infrastructuredetection sensitivitydisorder controlexhaustgenome-widegenomic toolsimmune checkpoint blockadeimmunogenicimprovedinsightmelanomaneoantigen vaccineneoantigensneoplastic celloverexpressionparallelizationreconstructionspatial integrationspatial relationshipsuccesstooltranscriptometranscriptome sequencingtreatment responsetumortumor immunologytumor microenvironmenttumor progression
项目摘要
The contemporary clinical successes of immunotherapies have highlighted the key role of tumor-infiltrating cells
in mediating anti-tumor immunity and have generally associated the presence of T cells within tumors with
therapeutic response. However, until now, a systematic approach for evaluating how T cell state, their clonal
identity and localization are related has not been possible. In recent years, the Wu lab has achieved several
notable technical advances, including generation of a best-in-class HLA class I epitope predictor (HLAthena); a
highly robust targeted plate-based method for single-cell TCR sequencing (rhTCRseq); and a means to
parallelize the cloning of hundreds of TCRs such that they can be interrogated to definitively link a TCR with its
antigen specificity. Because dynamic interactions between tumor-reactive T cells and malignant clones occur
within the defined spatial ordering of tissue, our valuable new insights motivate us to investigate how the spatial
organization of tumor-specific T cells relates to in situ positioning of tumor clones. We hypothesize that antigen
specificity, which drives the interactions between T cells and tumor cells, impacts the distinct regional localization
of T cells within the tumor microenvironment at baseline and in the context of therapy; conversely, that knowledge
of spatial localization identifies T cell clones specific for distinct antigen types. Slide-seq technology, created by
the Chen lab, provides a tractable and exciting path to investigate this hypothesis by implementing a scalable
approach to undertake in-depth analyses of informative human and murine tumor tissues. By expanding the
capabilities of this unbiased cellular resolution spatial capture method, we aim to gain tissue level understanding
of how the abundance and functional state of T cell clones and their spatial orientation within the tumor
microenvironment are linked. In particular, the study will address the spatial organization of T cell clones and
tumor subclones in human and mouse tumors. Our technology goals will be to increase the efficiency of
transcript capture of the technology, extend the capability to include robust detection of tumor mutations, and to
develop a suite of analytic tools to integrate in a multi model fashion the transcript, DNA-level and TCR levels of
information (Aims 1-2). Focusing on RCC tumors, we will evaluate the cell-cell localization patterns of T cell
clones in relation to tumor subclones and stromal cells through integrated spatial analyses of TCR and DNA
Slide-seq data (Aim 2). Finally, we will evaluate the impact of antigen specificity (definitively assessed by robust
TCR reconstruction and interrogation methods established in our lab) on T cell phenotype and localization using
TCR and DNA Slide-seq integrated spatial analyses at baseline and following immune checkpoint blockade and
neoantigen vaccine. (Aim 3) Altogether, we will develop and test these tools to understand spatially localized
cellular networks which drive immune response, and T-cell receptor relationships with the tumor
microenvironment. The completion of our work will yield a comprehensive toolset to enable a molecular,
cellular and histological understanding of the tumor immune response.
免疫疗法的当代临床成功突出了肿瘤浸润细胞的关键作用
在介导抗肿瘤免疫中的作用,并且通常将肿瘤内T细胞的存在与
治疗反应。然而,到目前为止,用于评估T细胞状态,其克隆
身份和本地化是不可能的。近年来,吴实验室已经取得了几项成果,
显著的技术进步,包括产生最佳的HLA I类表位预测因子(HLA抗原);
用于单细胞TCR测序的高度稳健的基于靶向板的方法(rhTCRseq);以及
并行克隆数百个TCR,使得它们可以被询问以确定性地将TCR与其受体连接。
抗原特异性因为肿瘤反应性T细胞和恶性克隆之间的动态相互作用发生
在定义的组织空间排序中,我们有价值的新见解促使我们研究空间
肿瘤特异性T细胞的组织涉及肿瘤克隆的原位定位。我们假设抗原
特异性驱动T细胞和肿瘤细胞之间的相互作用,影响不同的区域定位,
T细胞在肿瘤微环境中的基线和治疗背景下;相反,
的空间定位鉴定T细胞克隆特异性不同的抗原类型。Slide-seq技术,由
Chen实验室提供了一个易于处理和令人兴奋的途径,通过实施一个可扩展的
方法进行深入分析的信息人类和小鼠肿瘤组织。通过扩大
这种无偏的细胞分辨率空间捕获方法的能力,我们的目标是获得组织水平的理解
T细胞克隆的丰度和功能状态以及它们在肿瘤中的空间定位
微环境是相通的。特别是,该研究将解决T细胞克隆的空间组织,
人和小鼠肿瘤中的肿瘤亚克隆。我们的技术目标将是提高
转录本捕获的技术,扩展能力,包括强大的检测肿瘤突变,
开发一套分析工具,以多模型方式整合转录本、DNA水平和TCR水平,
信息(目标1-2)。针对RCC肿瘤,我们将评估T细胞的细胞-细胞定位模式,
通过TCR和DNA的整合空间分析确定与肿瘤亚克隆和基质细胞相关的克隆
Slide-seq数据(目标2)。最后,我们将评估抗原特异性的影响(通过稳健的
我们实验室建立的TCR重建和询问方法)对T细胞表型和定位的影响,
基线和免疫检查点阻断后的TCR和DNA Slide-seq整合空间分析,
新抗原疫苗(Aim 3)总之,我们将开发和测试这些工具,以了解空间定位
驱动免疫反应的细胞网络,以及T细胞受体与肿瘤的关系
微环境我们工作的完成将产生一个全面的工具集,
肿瘤免疫反应的细胞和组织学理解。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Fei Chen其他文献
Fei Chen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Fei Chen', 18)}}的其他基金
Dissecting Nrf2-dependent HIF1a activation mechanism in arsenic-induced cancer stem-like cells
剖析砷诱导的癌症干细胞样细胞中 Nrf2 依赖性 HIF1a 激活机制
- 批准号:
10435281 - 财政年份:2021
- 资助金额:
$ 69.13万 - 项目类别:
Arsenic-Induced miRNA-199 and mriRNA-214 Deplete Mitochondrial DNA for the Generation of Cancer Stem-Like Cells
砷诱导的 miRNA-199 和 mRNA-214 消耗线粒体 DNA 以生成癌症干细胞样细胞
- 批准号:
10489836 - 财政年份:2021
- 资助金额:
$ 69.13万 - 项目类别:
Dissecting Nrf2-dependent HIF1a activation mechanism in arsenic-induced cancer stem-like cells
剖析砷诱导的癌症干细胞样细胞中 Nrf2 依赖性 HIF1a 激活机制
- 批准号:
10316248 - 财政年份:2021
- 资助金额:
$ 69.13万 - 项目类别:
Arsenic-Induced miRNA-199 and mriRNA-214 Deplete Mitochondrial DNA for the Generation of Cancer Stem-Like Cells
砷诱导的 miRNA-199 和 mRNA-214 消耗线粒体 DNA 以生成癌症干细胞样细胞
- 批准号:
10463263 - 财政年份:2021
- 资助金额:
$ 69.13万 - 项目类别:
Reduced Reactive Oxygen Species and Oxidative Phosphorylation in Arsenic-Induced Cancer Stem Cells
砷诱导的癌症干细胞中活性氧的减少和氧化磷酸化
- 批准号:
10441939 - 财政年份:2021
- 资助金额:
$ 69.13万 - 项目类别:
Dissecting Nrf2-dependent HIF1a activation mechanism in arsenic-induced cancer stem-like cells
剖析砷诱导的癌症干细胞样细胞中 Nrf2 依赖性 HIF1a 激活机制
- 批准号:
10515655 - 财政年份:2021
- 资助金额:
$ 69.13万 - 项目类别:
A high-resolution molecular and lineage atlas of the mouse brain using Slide-seq
使用 Slide-seq 绘制小鼠大脑的高分辨率分子和谱系图谱
- 批准号:
10088261 - 财政年份:2020
- 资助金额:
$ 69.13万 - 项目类别:
A cellular atlas of the primate and human basal ganglia
灵长类动物和人类基底神经节的细胞图谱
- 批准号:
10527335 - 财政年份:2020
- 资助金额:
$ 69.13万 - 项目类别:
A single cell spatial genomics platform for multi-modal characterization of tissue organization
用于组织组织多模式表征的单细胞空间基因组学平台
- 批准号:
10408000 - 财政年份:2019
- 资助金额:
$ 69.13万 - 项目类别:
相似海外基金
Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
- 批准号:
10682121 - 财政年份:2023
- 资助金额:
$ 69.13万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10576370 - 财政年份:2022
- 资助金额:
$ 69.13万 - 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
- 批准号:
10387023 - 财政年份:2022
- 资助金额:
$ 69.13万 - 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10248409 - 财政年份:2019
- 资助金额:
$ 69.13万 - 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
- 批准号:
nhmrc : GNT1163111 - 财政年份:2019
- 资助金额:
$ 69.13万 - 项目类别:
Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
- 批准号:
10462684 - 财政年份:2019
- 资助金额:
$ 69.13万 - 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
- 批准号:
398018062 - 财政年份:2018
- 资助金额:
$ 69.13万 - 项目类别:
Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9308643 - 财政年份:2017
- 资助金额:
$ 69.13万 - 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
- 批准号:
9447149 - 财政年份:2017
- 资助金额:
$ 69.13万 - 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
- 批准号:
8893915 - 财政年份:2014
- 资助金额:
$ 69.13万 - 项目类别: